Prostate cancer has risen to become the most prevalent cancer in the UK, surpassing breast cancer, according to recent data from the NHS analyzed by Prostate Cancer UK. In 2022, 64,425 men were diagnosed with prostate cancer, compared to 61,640 diagnosed with breast cancer during the same period.
Despite the increasing awareness around prostate cancer screening, the UK National Screening Committee (UKNSC) rejected wider testing for men at higher risk, citing concerns about the reliability of blood tests and the potential for unnecessary treatment of benign tumors. Olympic champion Sir Chris Hoy, who is battling terminal prostate cancer, is advocating for proactive screening, especially for black men and those with a family history of the disease.
Sir Chris emphasized the importance of early detection, urging men to discuss the simple PSA blood test with their GPs. He praised the efforts of organizations like Prostate Cancer UK in encouraging more men to seek diagnosis and emphasized the need for continued awareness and action.
Prostate cancer cases are on the rise across the UK, with the disease now being the most common cancer in Scotland as well. Prostate Cancer UK attributes a 42% increase in diagnoses over the past decade to heightened awareness campaigns by charities, the NHS, and public figures.
The charity is pushing for broader adoption of the PSA test for screening and is conducting a significant clinical trial to explore the potential benefits of combining PSA with other tests like rapid MRI scans for widespread screening. While the UKNSC currently does not recommend routine PSA screening for most men, it suggests screening men with specific genetic mutations every two years.
Health Secretary Wes Streeting expressed surprise at the UKNSC’s decision and is reviewing the recommendations. Prostate Cancer UK is advocating for a shift in the system to enable more men to be diagnosed early, stressing the importance of proactive discussions between GPs and at-risk individuals.
The charity highlighted the constraints faced by GPs in initiating conversations with high-risk men due to outdated NHS guidelines. Concerns over the reliability of the PSA test have been raised, as elevated PSA levels may not always indicate cancer, leading to potential overtreatment and side effects.
As discussions continue on the best approach to prostate cancer screening, the focus remains on empowering men to understand their risk and engage in informed conversations with healthcare providers.